Remember, a dull knife still cuts. Go break some eggs.
👀 The Read
A mAb isn’t inherently “safe”.
Just because it’s a biologic doesn’t mean it’s easy.
Specificity reduces some risks and introduces others — a real mAb safety package plans for both.
Put an antibody into development and you'll often hear the same reassurance about nonclinical risk: not much — it's a mAb.
The logic sounds reasonable. Antibodies are highly specific. They’re made from “human” proteins, aren't metabolized into reactive intermediates, and they don't hit dozens of off-targets the way some small molecules do. So the safety work gets scaled down.
But specificity doesn't remove risk. It just moves it.
With a mAb, the risk you're most likely to see is the target itself: exaggerated pharmacology, when the drug does exactly what it was designed to do — just too much, or in the wrong tissue. Add immunogenicity: anti-drug antibodies that can change exposure, neutralize activity, or cause reactions of their own. For immunomodulatory targets, add cytokine release. And add tissue cross-reactivity: binding in tissues you weren't expecting.
None of these show up on a template built for small molecules. They show up when the package is designed around the biology of the target: which species actually express it and respond to it, what happens when it's blocked or activated too hard, and how ADA will affect your exposure data.
"Inherently safe" isn't a strategy. It's how a program ends up with no plan for the risk that actually materializes. Deciding which of those risks matter for your specific target is a different problem entirely.
The Misconception: mAbs are inherently safe, so the tox package is low risk.
The Correction: Antibody specificity lowers some risks but raises others. Build the package around the target's biology — exaggerated pharmacology, immunogenicity, cytokine release, tissue cross-reactivity — not a scaled-down small-molecule plan.
🤓 We cover this exact scenario in the course ↓
The Complete Guide to Nonclinical Development covers large molecule tox packages as well as ADA and immunogenicity over several lessons. Learn what’s needed for one, why, and how to interpret the data that comes from it.
You can now check out a Free Preview of the course, no strings attached:
